Socrata networkLive preview
Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction, United States
Published by National Center for Immunization and Respiratory Diseases (NCIRD)
About this dataset
Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction • Estimated nirsevimab coverage for children 0-19 months is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. • Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)
Live preview
The first rows, fetched from Socrata network when you open this page.
Loading the first rows from the source…